http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102084974-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28 |
| filingDate | 2016-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102084974-B1 |
| titleOfInvention | Pharmaceutical Compositions for Preventing or Treating Autoimmune Diseases Comprising Mesenchymal Stem Cells Derived from Human Bone-Marrow |
| abstract | The present invention provides a pharmaceutical composition for preventing or treating autoimmune diseases comprising human bone marrow-derived mesenchymal stem cells as an active ingredient. Human bone marrow-derived mesenchymal stem cells of the invention inhibit anti-dsDNA antibody, proteinuria and total IgG production, inhibit proliferation of T cells and B cells, and inhibit cytokine expression of T cells without toxicity. It is effective in preventing or treating autoimmune diseases. Lupus causes inflammation in the kidneys by autoantibodies and immunocomplexes, and increases the infiltration of immune cells. When the human bone marrow-derived mesenchymal stem cells of the present invention are administered, lupus is reduced by infiltrating immune cells into the kidneys. It has a prophylactic or therapeutic effect. |
| priorityDate | 2013-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 434.